Therapeutic agent for liver diseases
AssigneeAptabio Therapeutics Inc.
InventorsSung Hwan Moon, Soo Jin Lee, Sung Chan Lee, Yun Soo Bae
Life of this patent
Estimating the term…
Abstract
Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.
Claims10
A pharmaceutical composition for preventing, alleviating or treating a liver disease comprising, as an active ingredient, at least one compound selected from a pyrazole-based compound represented by the following Formula 1 and a pharmaceutically acceptable salt thereof:
- wherein R is a C1-C10 linear or branched alkyl group.
A therapeutic or prophylactic agent for simple steatosis comprising, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.
A therapeutic or prophylactic agent for non-alcoholic steatohepatitis comprising, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.
A therapeutic or prophylactic agent for cirrhosis comprising, as an active ingredient, at least one selected from 3-phenyl-4-normalpropyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.